Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas Jamal H. Carter, Samantha N. McNulty, Patrick J. Cimino, Catherine E. Cottrell, Jonathan W. Heusel, Katinka A. Vigh-Conrad, Eric J. Duncavage The Journal of Molecular Diagnostics Volume 19, Issue 2, Pages 328-337 (March 2017) DOI: 10.1016/j.jmoldx.2016.10.010 Copyright © 2017 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions
Figure 1 Schematic flow chart summarizing the diagnostic standing of various recurrent alterations in lower-grade gliomas according to the 2016 World Health Organization central nervous system tumor classification. The Journal of Molecular Diagnostics 2017 19, 328-337DOI: (10.1016/j.jmoldx.2016.10.010) Copyright © 2017 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions
Figure 2 Sequencing results organized by IDH1/2 and next-generation sequencing–based 1p/19q codeletion status. Variants displayed are those identified in genes that are either recurrently mutated or otherwise clinically actionable in lower-grade gliomas. Single-nucleotide polymorphisms (single-nucleotide variations in >1% of the population) were excluded. See Variant Annotation and Reporting for details. Boxes with multiple colors indicate more than one variant present. mut, mutant; WT, wild type. The Journal of Molecular Diagnostics 2017 19, 328-337DOI: (10.1016/j.jmoldx.2016.10.010) Copyright © 2017 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions
Figure 3 Heat map schematic of the next-generation sequencing–based copy number profiles of chromosomes 1 and 19 relative to the locations of the fluorescence in situ hybridization (FISH) probes used in conventional testing. Cases are grouped by IDH1/2 and next-generation sequencing–based 1p/19q codeletion status. Percentages indicate the variant allele frequency (VAF) of IDH1/2 mutants (mut), when present. WT, wild type. The Journal of Molecular Diagnostics 2017 19, 328-337DOI: (10.1016/j.jmoldx.2016.10.010) Copyright © 2017 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions